您的位置: 首页 > 农业专利 > 详情页

Treatment of glycogen synthase kinase-based disease
专利权人:
Jun Tan
发明人:
Jun Tan,Doug Shytle,Kavon Rezai-Zadeh
申请号:
US12020214
公开号:
US08778986B1
申请日:
2008.01.25
申请国别(地区):
US
年份:
2014
代理人:
摘要:
The bioflavonoid luteolin reduces amyloid-β peptide (Aβ) generation. Luteolin is also a selective GSK-3 inhibitor that 1) decreases amyloidogenic γ-secretase APP processing, and 2) promotes presenilin-1 (PS1) carboxyl-terminal fragment (CTF) phosphorylation. GSK-3α activity is essential for both PS1 CTF phosphorylation states and PS1-APP interaction. To validate The findings were validated in vivo, using a Tg2576 Alzheimers Disease model system. Luteolin treatment decreased soluble Aβ levels, reduced GSK-3 activity, and disrupted PS1-APP association.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/
相关发明人
相关专利

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充